Literature DB >> 6139123

Can the biochemical responses to a beta 2-adrenoceptor stimulant be used to assess the selectivity of beta-adrenoceptor blockers?

S Rolf Smith, M J Kendall, D J Worthington, R Holder.   

Abstract

The extent to which beta-adrenoceptor blocking drugs counteract the biochemical responses to an infusion of terbutaline, a beta 2-adrenoceptor agonist, has been investigated. In this study the beta 1-selectivity of metoprolol was compared with the non-selective beta-adrenoceptor blocker propranolol. The hypokalaemia produced by an infusion of terbutaline was reduced by low dose (50 mg) and high dose (200 mg) metoprolol and by low dose (40 mg) and high dose (160 mg) propranolol. The effects of propranolol on terbutaline induced hypokalaemia were more marked than those of metoprolol at both low dose (P = 0.01) and high dose (P = 0.05). Furthermore low dose metoprolol had less effect than high dose metoprolol (P = 0.05). The serum potassium appeared to rise slightly after propranolol. Low and high doses of both beta-adrenoceptor blockers markedly reduced the terbutaline-induced hyperglycaemia, but the differences between the two drugs were not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6139123      PMCID: PMC1428051          DOI: 10.1111/j.1365-2125.1983.tb02216.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Intravenous treatment with rimiterol and salbutamol in asthma.

Authors:  G E Marlin; P Turner
Journal:  Br Med J       Date:  1975-06-28

2.  Exercise responses of healthy subjects in the evaluation of cardioselectivity of beta-blockers.

Authors:  K L Woods; S P Linton; M J Kendall; E B Faragher; R J Grieve
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

3.  The action of beta-adrenergic blocking and stimulating agents on insulin secretion. Characterization of the type of beta receptor.

Authors:  A Loubatières; M M Mariani; G Sorel; L Savi
Journal:  Diabetologia       Date:  1971-06       Impact factor: 10.122

4.  Effects of adrenergic agonists and antagonists on potassium metabolism.

Authors:  R H Lockwood; B K Lum
Journal:  J Pharmacol Exp Ther       Date:  1974-04       Impact factor: 4.030

5.  The effect of beta, adrenergic blockade on serum potassium and glucose levels during open heart surgery.

Authors:  M C Petch; R McKay; D W Bethune
Journal:  Eur Heart J       Date:  1981-04       Impact factor: 29.983

6.  Effect of intravenous infusion of salbutamol on ventilatory response to carbon dioxide and hypoxia and on heart rate and plasma potassium in normal men.

Authors:  A G Leitch; L J Clancy; J F Costello; D C Flenley
Journal:  Br Med J       Date:  1976-02-14

7.  Cardiovascular and metabolic effects of terbutaline.

Authors:  M J Kendall; S Dean; D Bradley; R Gibson; D J Worthington
Journal:  J Clin Hosp Pharm       Date:  1982-03

8.  Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics.

Authors:  I Lager; G Blohmé; U Smith
Journal:  Lancet       Date:  1979-03-03       Impact factor: 79.321

9.  Metabolic and cardiovascular side effects of the beta 2-adrenoceptor agonists salbutamol and rimiterol.

Authors:  P J Phillips; A E Vedig; P L Jones; M G Chapman; M Collins; J B Edwards; T C Smeaton; B M Duncan
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

10.  Are selective beta-adrenoceptor blocking drugs an advantage?

Authors:  M J Kendall
Journal:  J R Coll Physicians Lond       Date:  1981-01
View more
  8 in total

Review 1.  Exercise metabolism and beta-blocker therapy. An update.

Authors:  A Head
Journal:  Sports Med       Date:  1999-02       Impact factor: 11.136

2.  Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta 2-adrenoceptor blockade.

Authors:  B J Lipworth; L C McFarlane; W J Coutie; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Effects of selective beta 2-adrenoceptor blockade on serum potassium and exercise performance in normal men.

Authors:  L Gullestad; K Birkeland; G Nordby; S Larsen; J Kjekshus
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

4.  Effect of CGP 17/582, a selective beta-adrenoceptor antagonist, on the haemodynamic and hypokalaemic response to adrenaline.

Authors:  K F Whyte; P J De Vane; R Whitesmith; A Kelman; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

5.  The impact of therapeutic reference pricing on innovation in cardiovascular medicine.

Authors:  Desmond Sheridan; Jim Attridge
Journal:  Pharmacoeconomics       Date:  2006-12       Impact factor: 4.981

Review 6.  Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.

Authors:  M J Kendall; S R Maxwell; A Sandberg; G Westergren
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 7.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

8.  Effect of adrenergic agonists on coronary blood flow: a laboratory study in healthy volunteers.

Authors:  Alvaro F Vargas Pelaez; Zhaohui Gao; Tariq A Ahmad; Urs A Leuenberger; David N Proctor; Stephan R Maman; Matthew D Muller
Journal:  Physiol Rep       Date:  2016-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.